Novartis Global Pipeline

Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development.

Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development.

For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2020.

Please note: the Novartis Pipeline data is updated quarterly.

Displaying 121 - 130 of 158 result(s)
Lead Indication

PDR001

spartalizumab

Malignant melanoma (combo)

Oncology

Phase 2

>=2025

PD1 Inhibitor (Anti-PD-1 monoclonal antibody)

PDR001

spartalizumab (combos)

Solid tumors (combo)

Oncology

Phase 1

PD1 Inhibitor (Anti-PD-1 monoclonal antibody)

Lead Indication

PHE885

PHE885

Haematological malignancy

Oncology

Phase 1

>=2025

BCMA cell therapy

QBW251

icenticaftor

Bronchiectasis

Respiratory Disease

Phase 2

CFTR Potentiator

Lead Indication

QBW251

icenticaftor

Chronic Obstructive Pulmonary Disease (COPD)

Respiratory Disease

Phase 2

2024

CFTR Potentiator

Lead Indication

QGE031

ligelizumab

Chronic urticaria (CSU)

Immunology, Hepatology and Dermatology

Phase 3

2022

IgE Inhibitor (High-affinity anti-IgE monoclonal antibody)

New Indication

QGE031

ligelizumab

CINDU

Immunology, Hepatology and Dermatology

Phase 3

2024

IgE Inhibitor (High-affinity anti-IgE monoclonal antibody)

New Indication

QGE031

ligelizumab

Food allergy

Immunology, Hepatology and Dermatology

Phase 3

>=2025

IgE Inhibitor (High-affinity anti-IgE monoclonal antibody)

New Indication

QMF149

Atectura®

Pediatric Asthma

Respiratory Disease

Phase 2

Indacaterol acetate +mometasone furoate

Supplementary Indication

RTH258

Beovu®

Diabetic Macular Edema (DME)

Ophthalmology

Phase 3

2021

VEGF Inhibitor (Anti-vascular endothelial growth factor single-chain antibody fragment)

Legend

Combination abbreviations:
fulv fulvestrant
tmx tamoxifen
gsn goserelin
NSAI Non-steroidal aromatase inhibitor
Taf Tafinlar® (dabrafenib)
Mek Mekinist® (trametinib)
a EU filing, approved in US.
b US filing, approved in EU.
c US filing, submitted in EU.
d US pending submission, approved in EU
e EU filing, submitted in US.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.